Germany is battling to slash drug prices domestically, all while expecting Americans to shoulder the rising costs. This stark contrast highlights the fierce struggle over global pharmaceutical pricing and market dominance
Browsing: pharmaceutical industry
Opioid maker Purdue Pharma is preparing to shut down as part of a groundbreaking $7.4 billion settlement addressing its role in the devastating opioid crisis. This historic agreement will deliver crucial funds straight to communities nationwide that have been deeply affected by the epidemic
Health Canada has just approved a generic version of Ozempic from Apotex, Canada’s leading drug manufacturer, opening the door to more affordable access to this popular medication for diabetes and weight management
Italy’s Chiesi is gearing up to acquire US-listed KalVista Pharmaceuticals for an impressive $1.9 billion, signaling a bold leap to expand its rare disease and drug development portfolio, Reuters reports. This landmark deal highlights the growing surge of cross-border investments transforming the pharmaceutical landscape
Big Pharma’s clinical trials in China are quietly bypassing global oversight, raising urgent alarms about data transparency and ethical practices. This emerging gap poses a serious risk to the trust and integrity of drug approvals worldwide
Global pharmaceutical giants are turbocharging their investments in Chinese drugmakers, eager to seize the explosive growth of the country’s biotech sector and tap into its enormous market potential. This bold strategic move is transforming the industry landscape like never before
Ozempic, the celebrated medication known for managing diabetes and aiding weight loss, is set to launch in generic form soon in India, China, and Canada-offering a promising path to more affordable access as global demand skyrockets, reports The New York Times
Generic Ozempic is set to revolutionize access for billions worldwide, making this breakthrough diabetes and weight management medication more affordable than ever. Experts foresee a game-changing shift in how treatments are delivered and priced across the globe
China is targeting the globe’s most expensive drugs with a bold mission: to dramatically cut costs and make life-saving treatments accessible to more patients. This ambitious move is shaking up the global pharmaceutical scene, transforming pricing strategies and sparking fresh waves of innovation throughout the industry
China is boldly challenging the U.S.’ leadership in pharmaceutical manufacturing as the Trump administration shakes up research policies. This dramatic shift sparks worries about America’s future grip on drug-making supremacy
AstraZeneca is making a bold leap with a $15 billion investment in China through 2030, cementing its role as a leader in next-generation innovative medicine and expanding its presence in one of the world’s fastest-growing healthcare markets
Canada is set to emerge as a key contender in the global race to produce generic versions of Ozempic, the popular diabetes medication, as manufacturers prepare for accelerated approvals and exciting new market opportunities on the horizon
Samsung Bioepis has just reached a thrilling milestone by securing Japan’s regulatory approval for its Stelara biosimilar, opening the door to a powerful presence in Asia’s rapidly growing biologics market, The Korea Herald reports
The US has announced an exciting plan to cut biosimilar development costs by 50% for India’s Biocon, a top executive told Reuters. This ambitious move aims to boost access to affordable biologics and strengthen the growing pharmaceutical alliance between the US and India
Novo Nordisk (NVO:NYSE) has boldly cut the price of its weight-loss drug Wegovy in India, making it more affordable and set to take the lead in the fast-growing obesity treatment market
Australia’s Neuren Pharma shares plunged to their lowest level in more than two months after the company dramatically cut its royalty forecast, sparking investor concerns over potential profit declines. Market watchers remain on edge as the stock faces renewed selling pressure
RAMM Pharma Corp. has just shared a crucial update regarding the Canada Post strike, warning shareholders that there may be delays in receiving the company’s meeting materials. Stay alert and watch your inbox for the latest news!
MercadoLibre (MELI) shares dipped after the e-commerce giant made a daring move into Brazil’s pharmacy market. With competition intensifying, investors are closely watching to see what this bold step means for the company’s future. Could this be your next big chance to buy in?
Eli Lilly is gearing up to invest over $1 billion in India, dramatically boosting its manufacturing power to keep pace with the skyrocketing demand across the region, Reuters reports
Advocacy groups are urging regulators to launch a bold anticompetition probe into Big Pharma’s moves after Brexit, accusing the industry of manipulating the market and driving prices sky-high. This call highlights growing concerns over pharmaceutical practices in the evolving post-Brexit landscape